Open AccessBack to the basics: How the preclinical rationale shapes the immunotherapy landscape for hepatocellular carcinoma
Author(s) -
D’Alessio Antonio,
Rimassa Lorenza
Publication year - 2021
Publication title -
liver cancer international
Language(s) - English
Resource type - Journals
ISSN - 2642-3561
DOI - 10.1002/lci2.24
Subject(s) - atezolizumab , medicine , pembrolizumab , nivolumab , sorafenib , immunotherapy , oncology , bevacizumab , hepatocellular carcinoma , ramucirumab , monoclonal antibody , durvalumab , pd l1 , cancer , cancer research , immunology , antibody , chemotherapy